Nektar Therapeutics has received FDA approval to test an investigational new drug as a potential treatment for mild COVID-19 cases. Nektar, which is based in California with major facilities in Huntsville and in India, is evaluating its bempegaldesleukin (BEMPEG, NKTR-214) to see whether the drug’s ability to stimulate lymphocyte production could improve treatment of COVID-19…
